Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
MAXILUS
2023-504541-31-00Phase 3Authorised
- Sponsor
- Celgene Corporation
- Start
- Mar 2024
- Modality
- Fc-Fusion Proteins → Carrier/Scaffold Proteins → Recombinant Proteins and Enzymes
- Countries
- 8
01
Overview
Phase 3, open-label trial of luspatercept in myelodysplastic syndrome (MDS) (2 cohorts), sponsored by Celgene Corporation. Primary endpoint: Composite primary efficacy endpoint. Planned start Mar 2024; status: authorised.
02
Drugs
luspatercept
03
Conditions
myelodysplastic syndrome (MDS)
Beyond the preview
Go deeper on 2023-504541-31-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2023-504541-31-00.